BioSpace News Archive

MediWound Ltd. announced Financial results for the first quarter ended March 31, 2022.

First Wave BioPharma, Inc. announced, that James Sapirstein, Chairman and Chief Executive Officer, will participate in a “fireside chat” with Yi Chen, Ph.D., Managing Director, Equity Research at H.C. Wainwright & Co., LLC, during the H.C. Wainwright Global Investment Conference taking place May 23-26, 2022, at Fontainebleau Miami Beach Hotel in Miami Beach, Florida.

Nurix Therapeutics, Inc. announced that the first patient has been dosed in its Phase 1a/1b study to evaluate orally available small molecule NX-5948, a potent and selective degrader of Bruton’s tyrosine kinase in patients with relapsed B-cell malignancies.

Milestone Scientific Inc. provided a business update and announced financial results for the first quarter ended March 31, 2022.

Talaris Therapeutics, Inc. announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company’s Board of Directors.

Kraig Biocraft Laboratories, Inc., the biotechnology company focused on the development and commercialization of spider silk, announces the first sample shipment of its recombinant spider silk fibers and fabrics for use and evaluation into a range of biomedical applications.

IN8bio, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, announced data emerging from the Company’s recently unveiled iPSC-based gamma-delta T cell platform.

Codiak BioSciences, Inc. announced new preclinical data on the Company’s engEx-AAV™ discovery program, a novel strategy that aims to leverage exosomes to improve adeno-associated virus vector gene therapy.

Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease announced that Gail McIntyre, Ph.D, DABT, Chief Executive Officer will present at the H.C. Wainwright Annual Global Investment Conference being held at the Fontainebleau Miami Beach Hotel May 23-26, 2022.

Aileron Therapeutics announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. ET in Miami, FL.